Generation of robust resident memory T cells in barrier tissues through skin vaccination
通过皮肤疫苗接种在屏障组织中生成强大的常驻记忆 T 细胞
基本信息
- 批准号:10408492
- 负责人:
- 金额:$ 44.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-07 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAntibodiesCOVID-19CellsDiseaseEpidemicFutureGenerationsHumanImmunityLung diseasesMiddle East Respiratory SyndromePatientsSevere Acute Respiratory SyndromeT memory cellT-LymphocyteTissuesVaccinesVirusbasebetacoronavirusdesignnovel strategiesrespiratory pathogenskin vaccinationvaccine delivery
项目摘要
SUMMARY
COVID 19, the lower respiratory disease caused by the 2019 nCov virus, is the latest betacoronavirus to cause
epidemic disease in humans. Previously, SARS and MERS, both cause by related viruses, emerged and fell
dormant as epidemics. Betacoronaviruses use homologous “Spike” proteins to bind mammalian cells for entry
and infection, and most vaccines are being built to generate neutralizing antibodies to the unique 2019 nCov
Spike protein. In contrast, we are trying to create a “universal” betacoronavirus vaccine base on T cell
immunity, using proteins conserved between all known coronaviruses as immunogens. These proteins,
expressed by MVA vectors and delivered by epidermal disruption, should provide broad and durable
pulmonary immunity to past, present, and future betacoronavirus threats.
总结
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis.
- DOI:10.1038/s41586-021-04384-4
- 发表时间:2022-03
- 期刊:
- 影响因子:64.8
- 作者:
- 通讯作者:
CD1a selectively captures endogenous cellular lipids that broadly block T cell response.
CD1A选择性地捕获了广泛阻断T细胞反应的内源性细胞脂质。
- DOI:10.1084/jem.20202699
- 发表时间:2021-07-05
- 期刊:
- 影响因子:0
- 作者:Cotton RN;Wegrecki M;Cheng TY;Chen YL;Veerapen N;Le Nours J;Orgill DP;Pomahac B;Talbot SG;Willis R;Altman JD;de Jong A;Van Rhijn I;Clark RA;Besra GS;Ogg G;Rossjohn J;Moody DB
- 通讯作者:Moody DB
Spatially and cell-type resolved quantitative proteomic atlas of healthy human skin.
- DOI:10.1038/s41467-020-19383-8
- 发表时间:2020-11-05
- 期刊:
- 影响因子:16.6
- 作者:Dyring-Andersen B;Løvendorf MB;Coscia F;Santos A;Møller LBP;Colaço AR;Niu L;Bzorek M;Doll S;Andersen JL;Clark RA;Skov L;Teunissen MBM;Mann M
- 通讯作者:Mann M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rachael Ann Clark其他文献
Rachael Ann Clark的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rachael Ann Clark', 18)}}的其他基金
Skin Inflammation in Human Health and Disease, 2021
人类健康和疾病中的皮肤炎症,2021
- 批准号:
10222899 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
优化皮肤 T 细胞淋巴瘤高通量 TCR 测序的分析前样品处理
- 批准号:
10688079 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
优化皮肤 T 细胞淋巴瘤高通量 TCR 测序的分析前样品处理
- 批准号:
10814026 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
优化皮肤 T 细胞淋巴瘤高通量 TCR 测序的分析前样品处理
- 批准号:
10053369 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
优化皮肤 T 细胞淋巴瘤高通量 TCR 测序的分析前样品处理
- 批准号:
10247804 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Using human skin grafted mice to identify biomarkers of exposure and study effects of radiation on skin
使用人类皮肤移植小鼠来识别暴露的生物标志物并研究辐射对皮肤的影响
- 批准号:
10551268 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma
优化皮肤 T 细胞淋巴瘤高通量 TCR 测序的分析前样品处理
- 批准号:
10424577 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Using human skin grafted mice to identify biomarkers of exposure and study effects of radiation on skin
使用人类皮肤移植小鼠来识别暴露的生物标志物并研究辐射对皮肤的影响
- 批准号:
10112825 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Reversing immune evasion and enhancing immune detection with topical resiquimod
使用外用瑞西莫德逆转免疫逃避并增强免疫检测
- 批准号:
10241428 - 财政年份:2018
- 资助金额:
$ 44.38万 - 项目类别:
Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination
通过皮肤疫苗接种在屏障组织中生成强大的常驻记忆 T 细胞
- 批准号:
10064958 - 财政年份:2016
- 资助金额:
$ 44.38万 - 项目类别:
相似海外基金
mRNA Delivery of a Panel of Single-Domain Antibodies for Combinatorial Deciphering of Therapeutic Targets for Covid-19 Related Cytokine Release Syndrome
一组单域抗体的 mRNA 递送,用于组合破译 Covid-19 相关细胞因子释放综合征的治疗靶点
- 批准号:
10383635 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Analysis of severe COVID-19 factors -establishment of research basis focusing on anti-type I IFN antibodies-
COVID-19重症因素分析-以抗I型IFN抗体为重点的研究基础的建立-
- 批准号:
22K16369 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Design, development, and validation of an end-user assay for low-cost, on-site, and rapid quantification of COVID-19 antigen and antibodies
设计、开发和验证最终用户检测方法,以低成本、现场快速定量 COVID-19 抗原和抗体
- 批准号:
570531-2021 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Alliance Grants
Evaluation of COVID-19 antibodies, cell-mediated immunity and telomeres following COVID-19 immunization or natural infection in an immune compromised population: An HIV Cohort Study
在免疫受损人群中进行 COVID-19 免疫或自然感染后评估 COVID-19 抗体、细胞介导的免疫和端粒:一项 HIV 队列研究
- 批准号:
448972 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Operating Grants
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
COVID-19 变异补充剂 - 开发候选疫苗和单克隆抗体,以阻断新型冠状病毒 COVID-19 的传播。
- 批准号:
443201 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Operating Grants
COVID-19 Variant Supplement - A low-cost, portable, and decentralized microfluidic device for detecting SARS-CoV-2 neutralizing antibodies
COVID-19 变异补充剂 - 一种低成本、便携式、分散式微流体设备,用于检测 SARS-CoV-2 中和抗体
- 批准号:
443274 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Operating Grants
Measuring salivary antibodies (Abs) in COVID-19 vaccinated children
测量已接种 COVID-19 疫苗的儿童的唾液抗体 (Abs)
- 批准号:
459280 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Operating Grants
Design, development, and validation of an end-user assay for low-cost, on-site, and rapid quantification of COVID-19 antigen and antibodies
设计、开发和验证最终用户检测方法,以低成本、现场快速定量 COVID-19 抗原和抗体
- 批准号:
570531-2021 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Alliance Grants
SBIR Phase I: Medical Device to Isolate and Purify Therapeutic Antibodies from Recovered Donors (COVID-19)
SBIR 第一阶段:从康复捐献者中分离和纯化治疗性抗体的医疗设备 (COVID-19)
- 批准号:
2036188 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Standard Grant
STTR Phase I: A platform for the rapid discovery of human antibodies as therapeutics for infectious disease (COVID-19)
STTR 第一阶段:快速发现人类抗体作为传染病治疗药物的平台(COVID-19)
- 批准号:
2036233 - 财政年份:2021
- 资助金额:
$ 44.38万 - 项目类别:
Standard Grant